Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25


Focus On Asia


Data Analysis


R&D


Altimmune Outlines Pemvidutide Plans In MASH And Beyond

 
• By 

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Amgen Bullish On Uplizna As ‘New Standard Of Care’ In Myasthenia Gravis

 

In the crowded and competitive field of generalized myasthenia gravis, Amgen has faith that Uplizna’s twice-yearly administration will make it the treatment of choice.

Illexcor Stake Gets Zydus Once-Daily Candidate For Sickle Cell Disease

 
• By 

A stake acquisition in US venture Illexcor allows India's Zydus to get in on the ground floor for a potential once-daily sickle cell disease treatment. The candidate showed promising preclinical results in a field that has yielded mixed outcomes for global majors like Novartis, Pfizer and Novo Nordisk

Zealand Turnaround Complete In Three Years

 
• By 

CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.

Business


Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Roche’s big new obesity deal; J&J opts out of next-gen Darzalex; Arvinas and Pfizer’s protein degrader misses Phase III endpoint; Kelun wins first TROP2 ADC approval in lung cancer; and big name brands poised to lose US exclusivity.

Altimmune Outlines Pemvidutide Plans In MASH And Beyond

 
• By 

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

 

Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.

Amgen Bullish On Uplizna As ‘New Standard Of Care’ In Myasthenia Gravis

 

In the crowded and competitive field of generalized myasthenia gravis, Amgen has faith that Uplizna’s twice-yearly administration will make it the treatment of choice.

Scrip Originals


Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

 

Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On

 
• By 

Restructuring Edition: Biopharma companies used fourth-quarter updates to reveal job and program cuts to conserve cash, including Sutro, Agenus, Coherus, Inozyme and Atea. Also, Vincerx’s reverse merger was terminated and Vaccinex, Oncternal, Syros plan to voluntarily delist.

Stock Watch: Hesitant Vaccine Sales For CSL Reflect Wider Issues

 
• By 

CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.

Pipeline Watch: Nine Approvals And Fifteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.